Mingyuan Han1, Yutein Chung1, Jun Young Hong2, Charu Rajput1, Jing Lei1, Joanna L Hinde1, Qiang Chen1, Steven P Weng1, J Kelley Bentley1, Marc B Hershenson3. 1. Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Mich. 2. Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Mich. 3. Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Mich; Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Mich. Electronic address: mhershen@umich.edu.
Abstract
BACKGROUND: We have shown that rhinovirus, a cause of asthma exacerbation, colocalizes with CD68+ and CD11b+ airway macrophages after experimental infection in human subjects. We have also shown that rhinovirus-induced cytokine expression is abolished in Toll-like receptor (TLR2)-/- bone marrow-derived macrophages. OBJECTIVE: We hypothesize that TLR2+ macrophages are required and sufficient for rhinovirus-induced airway inflammation in vivo. METHODS: Naive and ovalbumin (OVA)-sensitized and challenged C57BL/6 wild-type and TLR2-/- mice were infected with RV1B, followed by IgG or anti-TLR2, to determine the requirement and sufficiency of TLR2 for rhinovirus-induced airway responses. Bone marrow chimera experiments using OVA-treated C57BL/6 and TLR2-/- mice were also performed. Finally, naive TLR2-/- mice underwent intranasal transfer of bone marrow-derived wild-type macrophages. RESULTS: RV1B infection of naive wild-type mice induced an influx of airway neutrophils and CD11b+ exudative macrophages, which was reduced in TLR2-/- mice. After allergen exposure, rhinovirus-induced neutrophilic and eosinophilic airway inflammation and hyperresponsiveness were reduced in TLR2-/- and anti-TLR2-treated mice. Transfer of TLR2-/- bone marrow into wild-type, OVA-treated C57BL/6 mice blocked rhinovirus-induced airway responses, whereas transfer of wild-type marrow to TLR2-/- mice restored them. Finally, transfer of wild-type macrophages to naive TLR2-/- mice was sufficient for neutrophilic inflammation after rhinovirus infection, whereas macrophages treated with IL-4 (to induce M2 polarization) were sufficient for eosinophilic inflammation, mucous metaplasia, and airways hyperresponsiveness. CONCLUSIONS: TLR2 is required for early inflammatory responses induced by rhinovirus, and TLR2+ macrophages are sufficient to confer airway inflammation to TLR2-/- mice, with the pattern of inflammation depending on the macrophage activation state. Copyright Â
BACKGROUND: We have shown that rhinovirus, a cause of asthma exacerbation, colocalizes with CD68+ and CD11b+ airway macrophages after experimental infection in human subjects. We have also shown that rhinovirus-induced cytokine expression is abolished in Toll-like receptor (TLR2)-/- bone marrow-derived macrophages. OBJECTIVE: We hypothesize that TLR2+ macrophages are required and sufficient for rhinovirus-induced airway inflammation in vivo. METHODS: Naive and ovalbumin (OVA)-sensitized and challenged C57BL/6 wild-type and TLR2-/- mice were infected with RV1B, followed by IgG or anti-TLR2, to determine the requirement and sufficiency of TLR2 for rhinovirus-induced airway responses. Bone marrow chimera experiments using OVA-treated C57BL/6 and TLR2-/- mice were also performed. Finally, naive TLR2-/- mice underwent intranasal transfer of bone marrow-derived wild-type macrophages. RESULTS: RV1B infection of naive wild-type mice induced an influx of airway neutrophils and CD11b+ exudative macrophages, which was reduced in TLR2-/- mice. After allergen exposure, rhinovirus-induced neutrophilic and eosinophilic airway inflammation and hyperresponsiveness were reduced in TLR2-/- and anti-TLR2-treated mice. Transfer of TLR2-/- bone marrow into wild-type, OVA-treated C57BL/6 mice blocked rhinovirus-induced airway responses, whereas transfer of wild-type marrow to TLR2-/- mice restored them. Finally, transfer of wild-type macrophages to naive TLR2-/- mice was sufficient for neutrophilic inflammation after rhinovirus infection, whereas macrophages treated with IL-4 (to induce M2 polarization) were sufficient for eosinophilic inflammation, mucous metaplasia, and airways hyperresponsiveness. CONCLUSIONS:TLR2 is required for early inflammatory responses induced by rhinovirus, and TLR2+ macrophages are sufficient to confer airway inflammation to TLR2-/- mice, with the pattern of inflammation depending on the macrophage activation state. Copyright Â
Authors: Dawn C Newcomb; Uma Sajjan; Suparna Nanua; Yue Jia; Adam M Goldsmith; J Kelley Bentley; Marc B Hershenson Journal: J Biol Chem Date: 2005-08-24 Impact factor: 5.157
Authors: Waltraud Eder; Walt Klimecki; Lizhi Yu; Erika von Mutius; Josef Riedler; Charlotte Braun-Fahrländer; Dennis Nowak; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2004-03 Impact factor: 10.793
Authors: Payal K Naik; Paul D Bozyk; J Kelley Bentley; Antonia P Popova; Carolyn M Birch; Carol A Wilke; Christopher D Fry; Eric S White; Thomas H Sisson; Nabihah Tayob; Barbara Carnemolla; Paola Orecchia; Kevin R Flaherty; Marc B Hershenson; Susan Murray; Fernando J Martinez; Bethany B Moore Journal: Am J Physiol Lung Cell Mol Physiol Date: 2012-10-05 Impact factor: 5.464
Authors: Karl J Staples; Timothy S C Hinks; Jon A Ward; Victoria Gunn; Caroline Smith; Ratko Djukanović Journal: J Allergy Clin Immunol Date: 2012-09-14 Impact factor: 10.793
Authors: J Kelley Bentley; Uma S Sajjan; Marta B Dzaman; Nizar N Jarjour; Wai-Ming Lee; James E Gern; Marc B Hershenson Journal: J Allergy Clin Immunol Date: 2013-05-31 Impact factor: 10.793
Authors: Benjamin L Unger; Andrea N Faris; Shyamala Ganesan; Adam T Comstock; Marc B Hershenson; Umadevi S Sajjan Journal: PLoS Pathog Date: 2012-10-04 Impact factor: 6.823
Authors: William J Sheehan; Jonathan M Gaffin; David B Peden; Robert K Bush; Wanda Phipatanakul Journal: J Allergy Clin Immunol Date: 2017-12 Impact factor: 10.793
Authors: Mingyuan Han; J Kelley Bentley; Charu Rajput; Jing Lei; Tomoko Ishikawa; Caitlin R Jarman; Julie Lee; Adam M Goldsmith; William T Jackson; Mark J Hoenerhoff; Toby C Lewis; Marc B Hershenson Journal: Mucosal Immunol Date: 2019-05-15 Impact factor: 7.313
Authors: Tatt Jhong Haw; Malcolm R Starkey; Stelios Pavlidis; Michael Fricker; Anya L Arthurs; Prema M Nair; Gang Liu; Irwan Hanish; Richard Y Kim; Paul S Foster; Jay C Horvat; Ian M Adcock; Philip M Hansbro Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-10-12 Impact factor: 5.464
Authors: James T VanLeuven; Benjamin J Ridenhour; Andres J Gonzalez; Craig R Miller; Tanya A Miura Journal: PLoS One Date: 2017-06-02 Impact factor: 3.240